Telotristat ethyl with PRRT in the treatment of well differentiated neuroendocrine tumors.

被引：0
|
作者：
Zhuang, Tony Z.
Muzahir, Saima
Murphy, Kristina D.
Akce, Mehmet
Alese, Olatunji B.
Gbolahan, Maria Diab Olumide B.
Shaib, Walid Labib
机构：
[1] Emory Univ, Sch Med, Atlanta, GA USA
[2] Dept Radiol & Imaging Sci, Atlanta, GA USA
[3] Emory Univ, Winship Canc Inst, Atlanta, GA USA
[4] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA USA
[5] Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA USA
[6] Dept Hematol & Med Oncol, Atlanta, GA USA
[7] Winship Canc Inst, Atlanta, GA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16205
引用
收藏
页码：E16205 / E16205
页数：1
相关论文
共 50 条
  • [1] Safety in Patients With Neuroendocrine Tumors Receiving Telotristat Ethyl (TE) With Peptide Receptor Radionuclide Therapy (PRRT)
    Chauhan, A.
    Binder, P.
    Tesfaye, E.
    Seth, K.
    Lapuerta, P.
    PANCREAS, 2021, 50 (03) : 447 - 448
  • [2] Treatment outcomes of well-differentiated high-grade (G3) neuroendocrine tumors.
    Liu, Alex John
    Ueberroth, Benjamin Edward
    Petty, Skye Buckner
    McGarrah, Patrick Walsh
    Kendi, Ayse T.
    Hobday, Timothy J.
    Halfdanarson, Thorvardur Ragnar
    Sonbol, Mohamad Bassam
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] Initial Treatment of Well-Differentiated Neuroendocrine Tumors
    Dasari, Arvind
    Yao, James
    ONCOLOGY-NEW YORK, 2014, 28 (11): : 945 - 947
  • [4] Immunostaining for c-kit (CD117) in well differentiated and poorly differentiated neuroendocrine tumors.
    Della Torre, S
    Bajetta, E
    Ferrari, L
    Procopio, G
    Collini, P
    Catena, L
    Ricotta, R
    Bidoli, P
    Denaro, A
    Martinetti, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 892S - 892S
  • [5] Efficacy and security of PRRT in well-differentiated and moderate-differentiated neuroendocrine tumors: a single center experience in Mexico
    Medina, Sevastian
    Garcia-Perez, Francisco-Osvaldo
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [6] The efficacy and safety of sunitinib in patients with advanced well-differentiated pancreatic neuroendocrine tumors.
    Raymond, Eric
    Kulke, Matthew H.
    Qin, Shukui
    Schenker, Michael
    Cubillo, Antonio
    Lou, Wenhui
    Tomasek, Jiri
    Thiis-Evensen, Espen
    Xu, Jianming
    Racz, Karoly
    Croitoru, Adina E.
    Khasraw, Mustafa
    Sedlackova, Eva
    Borbath, Ivan
    Ruff, Paul
    Oberstein, Paul Eliezer
    Ito, Tetsuhide
    Fernandez, Kathrine C.
    Rosbrook, Brad
    Fazio, Nicola
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [7] Temozolomide and capecitabine (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors.
    Dogan, Izzet
    Tastekin, Didem
    Karabulut, Senem
    Sakar, Burak
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [8] Real-world analysis of peptide receptor radionuclide therapy (PRRT) in the treatment of neuroendocrine tumors.
    Chau, Justin
    Yu, Nanmeng
    Bakeri, Hirva
    Menda, Yusuf
    Dillon, Joseph S.
    Chandrasekharan, Chandrikha
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] Characterization of a novel entity of high-grade well-differentiated colorectal neuroendocrine tumors.
    Punekar, Salman Rafi
    Masri-Lavine, Lena
    Hajdu, Cristina
    Newman, Elliot
    Becker, Daniel Jacob
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] Treatment of advanced disease in patients with well-differentiated neuroendocrine tumors
    Diane L Reidy
    Laura H Tang
    Leonard B Saltz
    Nature Reviews Clinical Oncology, 2009, 6 : 143 - 152
12345